Global CRO Chiltern joins ACRO

The Association of Clinical Research Organizations, which represents the CRO industry globally, is pleased to announce that Chiltern, headquartered in Berkshire, United Kingdom, has joined ACRO and that Glenn Kerkhof, Chiltern CEO, will be the company's representative to the Association.

“ACRO's membership is expanding internationally just as our focus is increasingly global in scale”

"We welcome Chiltern into ACRO and look forward to exchanging views and perspectives with Glenn as he represents one of the larger European-based CROs," said William Sharbaugh, ACRO Chair and COO of PPD.

Established in 1982, Chiltern is a leading global CRO with extensive experience conducting and staffing Phase I to Phase IV clinical trials. The company employs more than 1,400 people within 19 countries.

"ACRO's membership is expanding internationally just as our focus is increasingly global in scale," said Doug Peddicord, Ph.D., ACRO Executive Director. "We invite all CROs with global aspirations to demonstrate their commitment to the industry by joining ACRO."

SOURCE Association of Clinical Research Organizations (ACRO)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Sapio Sciences and Ultima Genomics partner to advance multi-omics research